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Abstract
Background: The development of non-small cell lung carcinoma proceeds through a series of
well-defined pathological steps before the appearance of invasive lung carcinoma. The molecular
changes that correspond with pathology changes are not well defined and identification of the
molecular events may provide clues on the progression of intraepithelial neoplasia in the lung, as
well as suggest potential targets for chemoprevention. The acquisition of anti-apoptotic signals is
critical for the survival of cancer cells but the pathways involved are incompletely characterized in
developing intra-epithelial neoplasia (IEN).
Methods: We used immunohistochemistry to determine the presence, relative levels, and
localization of proteins that mediate anti-apoptotic pathways in developing human bronchial
neoplasia.
Results: Bronchial epithelial protein levels of the phosphorylated (active) form of AKT kinase and
the caspase inhibitor cIAP-2 were increased in more advanced grades of bronchial IEN lesions than
in normal bronchial epithelium. Additionally, the percentage of biopsies with nuclear localization of
p65/RELA in epithelial cells increased with advancing pathology grade, suggesting that NF-κB
transcriptional activity was induced more frequently in advanced IEN lesions.
Conclusion: Our results indicate that anti-apoptotic pathways are elevated in bronchial IEN
lesions prior to the onset of invasive carcinoma and that targeting these pathways therapeutically
may offer promise in prevention of non-small cell lung carcinoma.
Background
Lung cancer is the leading cause of cancer mortality in
both men and women in the United States [1]. Non-small
cell lung carcinomas arise from the respiratory epithelium
and progress through well-defined pathological stages
prior to becoming invasive and metastatic tumors. While
many studies have identified lung tumor markers of clin-
ical or prognostic significance, survival rates for this
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the past 30 years. The slow advance in treating lung cancer
is due in part to continued gaps in our understanding of
the molecular mechanisms of lung tumorigenesis. Thus,
studies that aid in our understanding of molecular mech-
anisms of lung tumorigenesis are important steps towards
developing better detection, prevention and treatment of
this disease.
Evasion of apoptosis by tumor cells is a critical step during
tumorigenesis. The serine/threonine kinase Akt is a critical
mediator of anti-apoptotic signaling in eukaryotic cells
and is activated in a signaling cascade downstream of Ras
activation and phosphoinositide-3-kinase (PI3K) [2].
Amplification of PI3K is common in many tumor types,
including lung cancer [3-5] and in lung cancer is corre-
lated with increased phosphorylation of Akt [4]. Activa-
tion of Akt, as measured by phosphorylation of the
protein, is also increased in multiple tumor types includ-
ing lung cancer [6-10]. Increased phosphorylation of Akt
kinase has also been reported in developing bronchial
hyperplasias and dysplasias [7,11,12] and pre-neoplastic
atypical alveolar hyperplasia [13], indicating that activa-
tion of this pro-survival pathway may be a relatively early
event in lung tumorigenesis.
The NF-κB transcription factor family can stimulate both
pro- and anti-apoptotic signals. Many studies have
described a critical role for NF-κB activity in promoting
cell survival. Increased staining for NF-κB subunits has
been detected in breast [14] and cervical carcinoma [15].
Inhibition of NF-κB activity either pharmacologically or
genetically can sensitize tumor cells to pro-apoptotic
agents [16-19] or to tumor necrosis factor-α (TNF-α)
induced apoptosis [20]. Proteasome inhibition, which
blocks the degradation of inhibitor of κB (IκB) protein,
thus blocking NF-κB nuclear translocation and activation,
also sensitized NSCLC cells to apoptosis [21,22]. Simi-
larly, expression of a super-repressor form of IκBα sensi-
tized lung cancer cell lines to apoptosis-inducing drugs
[16,23]. The super-repressor form of IκBα, as well as a
dominant negative form of IKK, also blocked Ras-medi-
ated transformation of cells [24,25] and expression of the
IκB super-repressor inhibited anchorage independent
growth and metastatic spread of human lung cancer cell
lines in a tumor xenograft model [26]. Furthermore, Akt
can activate the transcriptional potential of the p65/RELA
subunit of NF-κB [27,28], providing a potential link
between Akt kinase activity and NF-κB activation. Western
blot analysis has demonstrated over expression of the p50
subunit of NF-κB in lung cancer [29], but localization of
NF-κB family members has not been described in lung
tumors. Nevertheless, abundant evidence links NF-κB
transcriptional activation with lung tumorigenesis.
Several NF-κB-regulated genes that function in control of
apoptosis have been described including cIAP-1, cIAP-2,
A1/Bfl1, Traf1, Traf2 and Bcl-XL [30-33]. cIAP-1 and -2 are
members of the baculoviral IAP repeat-containing (BIRC)
gene family. cIAP-2/BIRC3 is expressed in lung adenocar-
cinoma cell lines [34] and can be induced by TNF-α [35].
Elevated expression of cIAP-2/BIRC3 has been reported in
human NSCLC [36-38] and elevated expression of the
related proteins XIAP/BIRC4 and survivin/BIRC5 are also
seen in NSCLC [36,39], implicating the BIRC family of
proteins as important mediators of lung tumorigenesis.
While the expression of pro-survival genes has been exam-
ined in some detail in lung tumors, relatively few studies
have examined the expression of these proteins in pre-
neoplastic lesions. To determine the presence and abun-
dance of pro-survival proteins in developing lung neopla-
sia, we examined human bronchial biopsies of various
grades (normal, hyperplasia, mild, moderate and severe
dysplasia, carcinoma in situ and carcinoma) for the pres-
ence of phospho-Akt, p65/RELA and cIAP-2/BIRC3 and
determined their localization within cells. The results
obtained provide new insight into the distribution of pro-
survival genes in human lung neoplasia and pre-neopla-
sia. This information may be useful in designing studies to
test the importance of these pathways experimentally and
ultimately may lead to improved diagnostic or therapeutic
strategies for human lung cancer.
Methods
Description of samples
Bronchial biopsies were obtained during autofluores-
cence [40] bronchoscopic examination, formalin fixed
and embedded in paraffin. Five-micron sections were
stained with H&E, examined and scored for pathology
Table 1: 
Pathology Grade No. patients No. biopsies Median age Gender (% female)
Normal 10 12 62.7 70
Hyperplasia 11 11 64.3 45
Mild/Moderate Dysplasia 17 23 64.2 53
Severe Dysplasia/CIS 7 9 67.9 29
Carcinoma 22 24 60.5 77Page 2 of 13
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WHO classification [41]. A separate group of surgically
resected NSCLC samples (adenocarcinoma and squa-
mous cell carcinoma) was obtained from Surgical Pathol-
ogy at the University of Cincinnati. All human samples
were obtained under approved IRB protocols at the
respective institutions. Table 1 describes the general prop-
erties of the biopsies stained including age and gender.
Age and gender distribution among the groups was not
statistically significant (one way ANOVA, p = 0.558 for
age; Kruskal-Wallis one way ANOVA on ranks, p = 0.158
for gender). Of the 22 carcinomas where staging data was
available, 36% were stage IA, 23% stage IB, 9% stage IIB,
23% stage III or IV and 9% unclassified. Tumor stages
were assigned based on pTNM classifications according to
UICC guidelines [42].
Antibodies and Immunohistochemistry
Rabbit polyclonal antibodies for phosphorylated (Ser473,
catalog # 9277) and total Akt (catalog # 9272) were pur-
chased from Cell Signaling Technologies (Beverley, MA)
and were both used at 1:100 dilution. The p65/RELA anti-
body (catalog # ab7970) was purchased from Abcam
America (Cambridge, MA) and used at a 1:4000 dilution.
The cIAP-2/BIRC3 antibody (catalog # AF817) was from
R&D Systems (Minneapolis, MN) and used at a 1:500
dilution. Biotinylated goat anti-rabbit secondary antibody
and normal goat serum was from Vector Laboratories
(Burlingame, CA).
Paraffin embedded sections were deparaffinized through
xylene and a graded series of ethanols. Endogenous perox-
idase activity was quenched by incubation in 2% hydro-
gen peroxide in methanol for 15 minutes then cleared in
PBS for 5 minutes. High temperature antigen unmasking
in citrate buffer was used for all antibodies and carried out
as described previously [43]. Non-specific binding was
blocked by incubation with 5% normal goat serum in PBS
+ 0.2% Triton X-100 (blocking serum) for 2 hours at room
temperature. Slides were then incubated overnight at 4°C
with primary antibody at the appropriate dilution in
blocking serum. The next day slides were washed 5× for 5
minutes each in PBS + 0.2% Triton X-100 before addition
of secondary antibody. Secondary antibody was added at
a 1:200 dilution in PBS+Triton and incubated for 30 min-
utes at room temperature with shaking. Slides were then
washed 5× for 5 minutes each with PBS+Triton. A
Vectastain ABC kit (Vector Laboratories) was used to pre-
pare avidin-biotin complexes for detection of secondary
antibody. Antigen localization was enhanced with Ni-
DAB and Tris-cobalt [44] followed by counterstaining
with Nuclear Fast Red.
Evaluation of immunohistochemical staining and 
statistical analysis
Biopsies received a numerical score of 0 for negative stain-
ing, 1 for predominantly faint staining, 2 for predomi-
nantly moderate staining or 3 for predominantly strong
staining. For the purpose of this study, the bronchial biop-
sies were divided into 5 categories for phosphorylated Akt
and cIAP-2/BIRC3 analysis: normal, hyperplasia, mild
dysplasia or moderate dysplasia, severe dysplasia or carci-
noma in situ and carcinoma. For analysis of p65/RELA
nuclear translocation, the mild and moderate dysplasia
groups were analyzed separately as there was a large differ-
ence in the percentage of nuclear staining between these
two groups. No significant difference in staining intensity
between mild and moderate dysplasia was seen for phos-
phorylated Akt or cIAP-2/BIRC3. Statistical analysis was
performed using SigmaStat software (SyStat Software,
Inc.). Analysis of variance for each stain was calculated
using a Kruskal-Wallis chi-squared test. Pairwise compari-
sons were calculated using a non-parametric Mann-Whit-
ney rank-sum test. A p-value < 0.05 was considered
significant.
Results
Immunohistochemistry for Akt protein kinase
The serine-threonine kinase Akt is a central regulator of
cell survival and apoptosis that is itself activated by phos-
phorylation. Antibodies that specifically recognize the
phosphorylated form (Ser 473) were used to identify the
phosphorylated, and thus activated, form of Akt. Intensity
of staining was scored on a scale of 0 for negative, 1 for
predominantly faint staining, 2 for predominantly mod-
erate staining and 3 for predominantly strong staining. In
normal bronchial epithelium, phospho-Akt staining typi-
cally consisted of faint cytoplasmic stain with occasional
cells staining with a more intense nuclear pattern (Figure
1A). In some biopsies, there was a concentration of stain-
ing at the apical surface of the epithelium. The underlying
interstitial cells were predominantly negative. With
increasing pathological grade, there was an overall
increase in the intensity of phospho-Akt staining (Figure
1) and an increase in the IHC score (Figure 2A). As pathol-
ogy grade increased to mild, moderate and severe dyspla-
sia, there were also an increased number of cells with
nuclear staining for phospho-Akt (Figure 1B,1C and 1D)
in addition to an increase in cytoplasmic staining inten-
sity (analysis of variance analysis using the Kruskal-Wallis
Chi-square test, p = 0.018). In addition, pairwise compar-
isons using the non-parametric Mann-Whitney rank-sum
test indicated that staining intensity of the mild/moderate
dysplasia and severe dysplasia/CIS groups were signifi-
cantly increased compared to normal (p = 0.02 and 0.004,
respectively). Similar to what has been previously
reported [12], invasive carcinoma had a lesser degree of
staining than advanced pre-neoplastic lesions (Figure 2A).Page 3 of 13
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plasma membrane associated staining for phospho-Akt
(Figure 3A), while an antibody that recognized both phos-
phorylated and unphosphorylated Akt showed equal
staining throughout the cytoplasm and nucleus (Figure
3B).
Immunohistochemistry for NF-κB subunit p65/relA
The transcription factor NF-κB is activated following Akt
phosphorylation via several mechanisms and is in itself
known to play a role in cell survival and protection from
apoptosis. We thus characterized the immunohistochem-
ical staining pattern of the NF-κB subunit p65/RELA in
pre-neoplastic bronchial biopsies. NF-κB subunits are
normally held in the cytoplasm, thus preventing them
from activating transcription, and are translocated to the
nucleus following various activation signals such as oxida-
tive stress or growth factor/cytokine stimulation. We
therefore determined the staining pattern of p65/RELA in
the cytoplasmic or nuclear compartment of airway epithe-
lial cells. Faint to moderate cytoplasmic staining for p65
was present in the cytoplasm of epithelial cells in normal
biopsies with little staining in the underlying stroma (Fig-
ure 4A and 4B). However, with the exception of one iso-
lated cluster of cells in a single biopsy, p65/RELA staining
was not present in the nucleus. With increasing pathology
Immunohistochemical localization of phospho-Akt in human bronchial biopsiesFigure 1
Immunohistochemical localization of phospho-Akt in human bronchial biopsies. Sections from human bronchial 
biopsies were incubated with antibodies specific for the phosphorylated form (ser473) of Akt, color developed with nickel-
DAB (black) and counterstained with nuclear fast red. Representative stains of normal (A), mild dysplasia (B), moderate dyspla-
sia (C) and severe dysplasia (D).Page 4 of 13
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Frequency plots of predominant IHC score for phospho-Akt and cIAP-2/BIRC3 in human pre-neoplastic bronchial biopsiesigur  2
Frequency plots of predominant IHC score for phospho-Akt and cIAP-2/BIRC3 in human pre-neoplastic bron-
chial biopsies. Pre-neoplastic biopsies were scored based on the predominant staining intensity observed using a scale of 0 
for negative, 1 for faint, 2 for moderate and 3 for strong. Each symbol represents a separate biopsy and the horizontal line rep-
resents the mean score for each category: normal, hyperplasia, mild or moderate dysplasia, severe dysplasia or carcinoma in 
situ and carcinoma. (A), Scores for predominant phospho-Akt staining intensity. Mean scores were: normal, 1.0; hyperplasia, 
1.3; mild or moderate dysplasia, 2.0; severe dysplasia or carcinoma in situ, 2.6; carcinoma, 1.6. (B), Scores for predominant 
cIAP-2/BIRC3 staining intensity. Mean scores were: normal, 1.1; hyperplasia, 0.89; mild or moderate dysplasia, 0.86; severe dys-
plasia or carcinoma in situ, 1.8; carcinoma, 1.8.
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lium was seen in an increasing percentage of biopsies
(Table 2). There was also a trend towards increased inten-
sity of cytoplasmic staining with increasing pathology
grade (Figure 4). Analysis of variance gave a significant p-
value of 0.010 for differences in percent nuclear localiza-
tion of p65 among the groups. Pairwise comparisons indi-
cated that moderate dysplasia and severe dysplasia/CIS
were significantly different from normal (p = 0.022 and
0.048, respectively). In normal bronchial epithelium,
staining of the submucosa was restricted to a few isolated
cells, however, many biopsies with moderate to severe
dysplasia showed intense staining in submucosal cells in
addition to intense epithelial staining (Figure 4C and 4D).
In NSCLC, nuclear localization of p65/RELA was seen
more frequently in squamous cell carcinomas (Figure 4E
and 4F) then adenocarcinomas. In all cases, nuclear p65/
RELA staining was focal within a biopsy.
Immunohistochemistry for cIAP-2
The inhibitor of apoptosis protein (IAP) family function
to block apoptosis by caspase-dependent and caspase-
independent means [45]. Several members of this family,
including cIAP-2, are known transcriptional targets of NF-
κB [31]. In normal bronchial epithelium, cIAP-2 staining
was typically present in a faint cytoplasmic pattern (Figure
5A). In some biopsies, a perinuclear pattern was observed
in epithelial basal cells (Figure 5A and 5B) and there were
scattered cells with positive nuclear stain. The average
intensity and localization of staining did not differ signif-
icantly from normal in hyperplasias or in mild to moder-
ate dysplasias (Figure 2B). Staining intensity was
increased in the severe dysplasia/CIS category and in car-
cinomas (Figure 5C). Strong perinuclear and nuclear
staining was common and more widespread in the higher
pathology grades compared to normal. Staining of cells in
the submucosa was also seen more frequently in the
higher pathology grades (severe dysplasia/CIS and carci-
noma) compared to normal (Figure 5C). Analysis of vari-
ance on cIAP-2 staining intensity indicated a significant
difference among the groups (p = 0.048).
Immunohistochemical localization of phospho-Akt and total Akt in human squamous cell carcinomaFigure 3
Immunohistochemical localization of phospho-Akt and total Akt in human squamous cell carcinoma. Serial sec-
tion from human squamous cell carcinoma was stained with antibodies specific for phospho-Akt (ser473) (A), or an antibody 
that recognizes both phosphorylated and non-phosphorylated forms of Akt (B). Localization of phospho-Akt to the plasma 
membrane of a subset of tumor cells is apparent. Incubation without primary antibody (C) was used as a negative control.
Table 2: Percent of biopsies with nuclear p65/RELA staining.
Pathology Grade % nuclear p65/RELA stain
Normal 11 (n = 9)
Hyperplasia 20 (n = 10)
Mild Dysplasia 10 (n = 10)
Moderate Dysplasia 73 (n = 11)
Severe dysplasia/CIS 71 (n = 7)
Carcinoma 41 (n = 17)Page 6 of 13
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Nuclear translocation of p65/RELA in progressing lung neoplasiaFigure 4
Nuclear translocation of p65/RELA in progressing lung neoplasia. Photomicrographs of normal bronchial epithelium 
(A, B), moderate dysplasia (C, D), or squamous cell carcinoma (E, F) at low (A, C and E) or high (B, D and F) magnification. 
Staining is diffusely cytoplasmic in normal bronchial epithelium. Nuclear translocation of p65/RELA, rarely detected in normal 
bronchial epithelium, is present in an increased percentage of moderate to severe dysplasias and squamous cell carcinoma 
(arrows, D and F).
BMC Cancer 2005, 5:155 http://www.biomedcentral.com/1471-2407/5/155Correlation between cIAP-2 and phospho-Akt staining 
intensity
We compared staining intensity of phospho-Akt and cIAP-
2 in biopsies where both stains were performed on serial
sections (n = 53). There was a significant correlation
between phospho-Akt and cIAP-2 staining intensities in
these biopsies (Spearman correlation coefficient, r =
0.484, p = 0.0002). This correlation was seen at all pathol-
ogy grades.
The cIAP-2 gene is a transcriptional target for NFκB activa-
tion [31]. To examine whether cIAP-2 expression was
increased specifically in areas of nuclear p65/RELA stain-
ing, we examined serial sections of biopsies stained with
both antibodies. AN example of serial sections of a mod-
erate dysplasia (Figure 6A–C) demonstrates nuclear p65/
RELA staining accompanied by increased staining inten-
sity of phospho-Akt and cIAP-2. An adenocarcinoma with
strong cytoplasmic staining for p65/RELA with moderate
staining for phospho-Akt and cIAP-2 is also shown (Fig-
ure 6D–F). Co-localization of nuclear p65/RELA staining
and increased cIAP-2 staining was not a consistent obser-
vation, and elevated cIAP-2 staining was seen in bronchial
IEN lesions without detectable nuclear staining for p65/
RELA. Additionally, even in biopsies with nuclear locali-
zation of p65/RELA, the number of cells with nuclear
Immunohistochemical localization of cIAP-2/BIRC3Figure 5
Immunohistochemical localization of cIAP-2/BIRC3. Photomicrographs of normal bronchial epithelium (A), mild dys-
plasia (B), severe dysplasia (C) and a negative control processed without primary antibody (D). In normal and mild dysplasia, 
perinuclear staining was observed, predominantly in cells adjacent to the basement membrane (for example, arrow in panel B). 
Increased staining intensity and increased frequency of nuclear staining was observed in severe dysplasias (panel C).Page 8 of 13
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increased cIAP-2 staining intensity. Thus, there was not a
clear correlation between nuclear p65/RELA staining and
increased staining intensity for cIAP-2 in human bron-
chial IEN lesions or human NSCLC.
We also examined if there was a correlation between
tumor stage and staining intensity or nuclear localization
of p65/RELA in carcinomas. No correlation was seen
between tumor stage and any of the stains examined.
Discussion
The pathways utilized by lung tumors to evade apoptosis,
allowing the tumors continued survival and growth, are
incompletely characterized. Equally important are the
pathways that become activated in IEN lesions before they
become invasive cancer. In this study, we examined the
presence and cellular localization of the phosphorylated
form of Akt kinase, the transcription factor p65/RELA and
the cellular inhibitor of apoptosis protein cIAP-2/BIRC3
in human bronchial IEN lesions. In normal human bron-
chial epithelium, staining for phosphorylated Akt was
present as a faint cytoplasmic stain. Staining intensity
increased with increasing pathology grade and was
present in a nuclear, perinuclear or plasma membrane
pattern. The intensity of p65/RELA staining also increased
with increasing pathology grade. Furthermore, more
biopsies had nuclear localization of p65/RELA with
advancing pathology grade, indicating nuclear transloca-
tion of the protein and the potential for transcriptional
activation. The apoptosis inhibitor cIAP-2/BIRC3 also had
increased staining intensity with increasing pathology
Staining for p65/RELA, phospho-Akt and cIAP-2 on serial biopsy sectionsFigure 6
Staining for p65/RELA, phospho-Akt and cIAP-2 on serial biopsy sections. Serial sections from a moderate dysplasia 
(A–C) or adenocarcinoma (D–F) underwent immunohistochemical staining with antibodies directed against p65/RELA (A and 
D), phospho-Akt (B and E) or cIAP-2 (C and F). Cells with nuclear localization of p65/RELA (arrows in A) correlated with 
regions of increased staining for phospho-Akt and cIAP-2 in this moderate dysplasia but the correlation was not consistently 
observed. High levels of cytoplasmic p65/RELA staining in the adenocarcinoma corresponded with faint to moderate staining 
for phospho-Akt and cIAP-2 (D–F). There was a statistically significant correlation between cIAP-2 and phospho-Akt staining 
intensity at all pathology grades.Page 9 of 13
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2/BIRC3, components of an anti-apoptotic pathway, are
elevated in pre-neoplastic lung lesions.
The serine/threonine kinase Akt is a central mediator of
anti-apoptotic pathways in eukaryotic cells [2]. Activation
of this kinase occurs when it is itself activated by PI3K-
dependent protein kinase 1 or 2 (PDK1 or 2). Previous
studies have noted an increase in the amount of phospho-
rylated Akt in a number of different human malignancies
including cancer of the lung [4,7,12], head and neck [46],
prostate [9], and in multiple myeloma [8,47]. In addition,
loss of the tumor suppressor phosphatase and tensin
homologue (PTEN), a lipid phosphatase that inhibits
PI3K activity, is found in a subset of lung tumors [48-50].
Increased staining for phosphorylated Akt was also fre-
quently observed in human bronchial pre-neoplastic
lesions [4,7,12]. In bronchial IEN, increased staining for
phospho-Akt correlated with increased staining for phos-
pho-FKHR, a transcription factor that directs expression of
anti-apoptotic genes in response to Akt signaling [7]. Our
present results agree with previous studies demonstrating
an increase in phospho-Akt staining in pre-neoplastic
human bronchial lesions. We observed increased staining
for the phosphorylated form of Akt beginning as early as
mild dysplasia lesions in human bronchial biopsies.
The staining for phospho-Akt observed in the biopsies in
our study was diverse, consisting of cytoplasmic, nuclear
or plasma membrane associated patterns. As PDK must
associate with PI3K at the plasma membrane to be acti-
vated, localization of Akt has often also been localized to
the cytoplasm or plasma membrane [8,9]. However, sev-
eral targets of Akt are nuclear transcription factors and
nuclear localization of Akt has been described in several
other human tumor types [7,12,47]. The differences in
subcellular localization observed for phospho-Akt in dif-
ferent biopsies may reflect the large number of pathways
regulated by this kinase and the different mechanisms by
which Akt can mediate its anti-apoptotic effects. The func-
tional significance of the variable localization of phos-
pho-Akt in human lung tumors remains to be
determined.
The NF-κB transcription factor family is known to direct
both apoptotic and anti-apoptotic signaling in eukaryotic
cells [51]. In unstimulated cells, NF-κB transcription com-
plexes are held in the cytoplasm by IκB proteins, thus pre-
venting their function as transcriptional activators in the
nucleus. Cytokine or growth factor stimulation initiates a
signaling cascade that leads to activation of the IκB kinase
(IKK) complex that in turn phosphorylates IκB and targets
it for ubiquitination and ultimately degradation by the
proteasome. Degradation of IκB allows NF-κB to be trans-
located to the nucleus where it can activate transcription
of target genes. Inhibition of NF-κB blocked Ras-mediated
transformation of cell lines [24] indicating NF-κB activity
is critical for Ras-mediated transformation. The Akt kinase
has been reported to activate NF-κB by phosphorylation
of IKK [52], causing degradation of IκB and nuclear trans-
location of NF-κB complexes, and by directly phosphor-
ylating the p65/RELA subunit of NF-κB and increasing its
transcriptional activity [27,28]. It should also be noted
that Akt can be activated by NF-κB [53], suggesting the
regulatory pathways utilized by these molecules is com-
plex.
While ample evidence has implicated NF-κB activation as
playing an important role in cell transformation, particu-
larly in vitro, there is little data on the presence or locali-
zation of NF-κB components in human lung tumors.
Chemotherapeutic agents induced NF-κB activity in
NSCLC cell lines, increasing the cells resistance to these
agents [17] suggesting that in addition to a role in tumor
cell evasion of apoptosis, NF-κB may render lung tumor
cells more resistant to chemotherapeutic agents. The NF-
κB subunit p50 was increased in NSCLC as detected by
immunoblotting but no information on localization of
this protein within tumors was obtained [29]. To our
knowledge, no other study has examined the localization
of the p65 subunit of NF-κB in lung IEN lesions or
NSCLC. We therefore decided to examine human IEN
lesions and lung carcinomas for the presence and localiza-
tion of the p65/RELA subunit of NF-κB.
In our study, nuclear translocation of the p65/RELA subu-
nit of NF-κB was significantly increased in moderate dys-
plasias compared to lower grade lesions. In the
carcinomas, there was a reduction of p65/RELA nuclear
positivity similar to the decreased intensity of phospho-
Akt staining observed in carcinomas compared to moder-
ate and severe dysplasias. The percentage of cells with pos-
itive nuclear staining in carcinomas was also very low
compared to moderate and severe dysplasias generally
being restricted to isolated foci. In addition to the
increased number of biopsies with nuclear staining at
higher pathology grades, the overall intensity of cytoplas-
mic tended to be increased in moderate dysplasias in both
the epithelium and stroma compared to normal epithe-
lium (although this difference was not statistically signifi-
cant in our analysis). In a number of carcinomas, there
was intense cytoplasmic staining for p65/RELA with an
apparent paucity of staining in the nucleus. While these
biopsies were scored negative for nuclear staining of p65/
RELA, it was impossible to discount the possibility that
nuclear p65/RELA was present in these cells but at levels
lower than those observed in the cytoplasm. In the lung
adenocarcinoma cell line NCI-H441 we have also
observed higher levels of p65 immunoreactivity in the
cytoplasm than the nucleus although these cells have veryPage 10 of 13
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assays (JWT and MWA, unpublished data). It should also
be noted that activation of NF-κB has been reported in
lung cancer cells without an increase in nuclear localiza-
tion [24,54]. In all lesions with positive nuclear staining,
a majority of tumor cells did not contain nuclear p65/
RELA staining. The focal nature of nuclear positivity may
reflect the induction of this pathway in a subset of cells
that has acquired new genetic or epigenetic changes that
activate NF-κB and thus may activate downstream anti-
apoptotic pathways.
Tumor cells acquire the ability to escape apoptosis that is
normally initiated in damaged cells. One mechanism for
inhibiting apoptosis is to block the activity of the effector
caspases that initiate apoptosis by degrading specific cel-
lular targets [55]. The cellular inhibitor of apoptosis
(cIAP) family of proteins, also known as the baculoviral
IAP repeat containing (BIRC) family, can inhibit apopto-
sis by binding effector caspases and blocking their proteo-
lytic activity. Several family members have been described
including cIAP-1/BIRC2, cIAP-2/BIRC3, XIAP/BIRC4, sur-
vivin/BIRC5 and NAIP/BIRC1, and are thought to be
important in tumorigenesis [45]. We chose to examine the
levels of cIAP-2/BIRC3 in developing lung neoplasia as it
is expressed in lung tissue [38] and is a target for NF-κB
transcriptional activation [31].
While increased staining for cIAP-2/BIRC3 in human lung
adenocarcinomas has been reported [38], levels of cIAP-2/
BIRC3 in IEN lesions in lung epithelium have not been
reported. Staining for cIAP-2/BIRC3 was increased in the
severe dysplasia/CIS category and in carcinomas com-
pared to less advanced pathology grades. The increase in
cIAP-2/BIRC3 staining occurred at a higher pathology
grade than the grade at which phospho-Akt staining
increased (mild/moderate dysplasias) or p65/RELA
nuclear localization was increased (moderate dysplasia).
This may indicate that inhibition of apoptosis via this pro-
tein is not required until later in lung tumorigenesis.
While high levels of cIAP-2/BIRC3 expression correlated
with nuclear localization of p65/RELA in some biopsies,
this was not a consistent observation. The lack of consist-
ent p65/RELA and cIAP-2/BIRC co-expression, in combi-
nation with the observation that the overall increase in
cIAP-2/BIRC staining occurred at a later pathological stage
than p65/RELA nuclear translocation, may indicate that
cIAP-2/BIRC3 is not a direct target of p65/RELA in bron-
chial pre-neoplasia. The possibility remains that p65/
RELA transcriptional activation initiates a program that
may indirectly lead to cIAP-2/BIRC3 induction later in the
progression of pre-neoplastic bronchial lesions.
While nuclear staining localization of p65/RELA and
increased staining for cIAP-2 did not correlate, we
observed a positive correlation between staining intensity
for cIAP-2 and phospho-Akt. While it is impossible to
state whether this indicates that cIAP-2 is regulated by
activation of Akt phosphorylation, this is a possibility. It
should be noted, however, that staining intensity for
phospho-Akt occurred one pathology grade prior to the
observed increase in cIAP-2 staining intensity.
Conclusion
Increased staining for phospho-Akt and cIAP-2/BIRC3 is
present in pre-neoplastic human bronchial biopsy lesions
compared to normal human bronchial epithelium. Addi-
tionally, the percentage of biopsies containing nuclear
p65/RELA staining is increased in pre-neoplastic lesions
compared to normal bronchial epithelium. The activation
of genes involved in protecting cells from apoptosis in
pre-neoplastic lesions suggests that the ability of lung epi-
thelial cells to evade apoptosis is acquired prior to the
cells becoming fully transformed. As pre-neoplastic
lesions have not acquired all the genetic and epigenetic
changes present in lung carcinoma, they may be more
amenable to treatment with chemopreventive agents.
Thus, identification of the pathways activated in human
bronchial pre-neoplastic lesions is important in increas-
ing our understanding of how these lesions develop into
lung cancer with the eventual goal of targeting these path-
ways therapeutically.
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